> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Unanimously Backs Non-Rx Narcan
- URL: https://www.fdaweb.com/panel-unanimously-backs-non-rx-narcan/
- Published: 2023-02-15T12:00:00.000Z
- Updated: 2026-09-14T18:15:58.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153791

A joint FDA Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Meeting unanimously voted 2/15 to recommend the nonprescription use of Emergent BioSolutions’ Narcan (naloxone HCl) nasal spray, 4 mg/.1 mL, for treating known or suspected opioid overdose.

The 19-0 vote came despite some panel members voicing concerns about an Emergent study that showed some users were confused by the drug’s instructions and packaging. The company agreed it would revise the labeling and packaging to address the concerns.

In reaction to the vote, the American Medical Association said: “Making naloxone over the counter is a safe and vital step to ending the nation’s overdose epidemic. This will help community-based organizations purchase and distribute naloxone to those who need it most. Rather than sitting behind a pharmacy counter, naloxone needs to be readily available to save lives.” The group urged FDA to make a quick final decision.